Recent Updates
Recently added Catalysts

Single dose of PF-07220060 as first Formulation

Phase 1

Healthy Participants | Small molecule | Other |Pfizer, Inc.|Last Updated: Jun 4, 2026

Target and mechanism

ModalitySmall molecule

Also known as Single dose of PF-07220060 as first Tablet Formulation

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment113

FDA Designations

No designations recorded

Clinical trial landscape

Single dose of PF-07220060 as first Formulation · 1 trial · 1 indication

Phase 1 1
NCT05923411A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy AdultsHealthy Participants
COMPLETED113 Analytics
PHASE1COMPLETED
A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults
Healthy Participants
NCT05923411113
Unlock trial analytics

Study Endpoints

Primary Endpoints

Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time(AUCinf) of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations
0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours PF-07220060 post-dose
Maximum Observed Plasma Concentration (Cmax) of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations
0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours PF-07220060 post-dose

Secondary Endpoints

AUCinf of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations at a second dose level
0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours PF-07220060 post-dose
Cmax of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations at a second dose level
0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours PF-07220060 post-dose
Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time(AUCinf) of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations (third formulation)
0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours PF-07220060 post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Cohort 1EXPERIMENTALParticipants will receive PF-07220060 tablet by mouth
Cohort 2EXPERIMENTALParticipants will receive PF-07220060 tablet by mouth
Cohort 3EXPERIMENTALParticipants will receive PF-07220060 tablet by mouth
Cohort 4EXPERIMENTALParticipants will receive PF-07220060 tablet by mouth
Cohort 5EXPERIMENTALParticipants will receive PF-07220060 tablet by mouth
Cohort 6EXPERIMENTALParticipants will receive PF-07220060 and Rabeprazole tablets by mouth
Cohort 7EXPERIMENTALParticipants will receive PF-07220060 and Rabeprazole tablet by mouth
Cohort 8EXPERIMENTALParticipants will receive PF-07220060 tablet by mouth

Interventions

NameTypeDescription
Single dose of PF-07220060 as first Tablet FormulationDRUGA single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.
Single dose of PF-07220060 as second Tablet FormulationDRUGA single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
Single dose of PF-07220060 as a Tablet FormulationDRUGA single dose of PF-07220060 as a tablet formulation administered under fed conditions
Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administrationDRUGA 2-treatment fixed sequence of single dose of PF-07220060 tablets under fasting conditions followed by a single dose of PF-07220060 tablets under Proton Pump Inhibitor (PPI) administration under fasting condition (following a 7 day oral rabeprazole tablets daily administration).
Single dose of PF-07220060 as third tablet formulationDRUGA 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring * BMI of 17.5-30.5 kg/m2; and a total body weight \>50 kg (110 lb). * Evidence of a personally sig...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMJul 5, 2026NCT05923411TRIAL_REMOVED: changed
MEDIUMJul 5, 2026NCT05923411TRIAL_REMOVED: changed
MEDIUMJul 5, 2026NCT05923411TRIAL_REMOVED: changed